Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium acetate + magnesium carbonate is an oral fixed-dose phosphate-binding medicine marketed as **OsvaRen** for hyperphosphataemia in adults with chronic kidney disease receiving dialysis. Each film-coated tablet contains calcium acetate 435 mg, providing 110 mg elemental calcium, and heavy magnesium carbonate 235 mg, providing 60 mg elemental magnesium. Taken with meals, its calcium and magnesium ions bind dietary phosphate in the gastrointestinal tract, forming poorly absorbed phosphate salts that are eliminated in faeces and thereby lower serum phosphate. The magnesium-containing formulation reduces calcium exposure relative to calcium-only phosphate binders, although serum calcium and magnesium require monitoring because hypercalcaemia and hypermagnesaemia may occur.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium acetate + magnesium carbonate.